Chemomab Therapeutics Ltd. (CMMB) 10-Year Financial Performance & Capital Metrics

CMMB • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutChemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.Show more

Revenue $0
EBITDA -$15M +42.2%
Net Income -$14M +42.4%
EPS (Diluted) -3.12 +62.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -91.34% -0.4%
ROIC -139.16% -13.0%
Debt/Equity 0.02 +3.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Shares diluted 52.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM21.27%

EPS CAGR

10Y-

5Y-

3Y-

TTM47.91%

ROCE

10Y Avg-195.26%

5Y Avg-65.32%

3Y Avg-82.69%

Latest-94.91%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	26.25K	40.64K	51K	66K	281.91K	80K	34.02K	57.77K	66.83K	53.25K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-26.25K	-40.64K	-51K	-65.78K	-282K	-80K	-34.02K	-57.77K	-66.83K	-53.25K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.55%	-0.25%	-0.29%	-3.29%	0.72%	0.57%	-0.7%	-0.16%	0.2%
Operating Expenses+	7.11M	4.59M	9.34M	12.97M	19.33M	5.97M	12.37M	28.53M	25.46M	14.74M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	1.14M	2.25M	3.11M	5.46M	5.98M	1.29M	6.03M	11.56M	7.08M	3.41K
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	5.96M	2.34M	6.23M	7.51M	13.35M	4.68M	6.33M	16.98M	18.38M	11.33K
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	14.72M
Operating Income+	-7.13M	-4.63M	-9.39M	-13.04M	-19.61M	-5.97M	-12.37M	-28.53M	-25.46M	-14.74M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	0.35%	-1.03%	-0.39%	-0.5%	0.7%	-1.07%	-1.31%	0.11%	0.42%
EBITDA+	-7.11M	-4.59M	-9.34M	-12.97M	-19.33M	-5.95M	-12.33M	-28.48M	-25.39M	-14.69M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	0.35%	-1.03%	-0.39%	-0.49%	0.69%	-1.07%	-1.31%	0.11%	0.42%
D&A (Non-Cash Add-back)	26.25K	40.64K	51K	66K	281.91K	24K	34.02K	57.77K	67K	53.25K
EBIT	-7.49M	-4.61M	-9.55M	-13.42M	-27.2M	-5.97M	-12.37M	-28.53M	-25.46M	-14.01M
Net Interest Income+	-13.13K	0	-4K	0	384K	14K	-111K	-1.38K	1.23M	797.77K
Interest Income	1.03K	521	1K	0	393K	20K	65	351.62K	1.24M	797.77K
Interest Expense	14.16K	0	5K	0	9K	6K	111.08K	353K	0	0
Other Income/Expense	-369K	36.33K	-91.71K	-456K	-7.6M	21K	-111K	353K	1.24M	794K
Pretax Income+	-7.5M	-4.61M	-9.56M	-5.87M	-27.21M	-5.95M	-12.48M	-28.18M	-24.22M	-13.95M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-3	136.24K	323K	306K	0	0	0	-534K	0	0
Effective Tax Rate %	1%	1.03%	1.03%	2.35%	1%	1%	1%	0.98%	1%	1%
Net Income+	-7.5M	-4.73M	-9.81M	-13.8M	-27.21M	-5.95M	-12.48M	-27.65M	-24.22M	-13.95M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	0.37%	-1.07%	-0.41%	-0.97%	0.78%	-1.1%	-1.22%	0.12%	0.42%
Net Income (Continuing)	-7.5M	-4.75M	-9.88M	-5.87M	-27.21M	-5.95M	-12.49M	-27.65M	-24.22M	-13.95M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-131.76	-69.00	-875.98	-87.09	-63.20	-25.21	-4.80	-9.68	-8.22	-3.12
EPS Growth %	-	0.48%	-11.7%	0.9%	0.27%	0.6%	0.81%	-1.02%	0.15%	0.62%
EPS (Basic)	-131.76	-69.00	-875.98	-87.09	-63.20	-25.21	-4.80	-9.68	-8.22	-3.12
Diluted Shares Outstanding	56.92K	67.92K	11.28K	157.93K	430.57K	463.74K	2.59M	2.84M	2.94M	4.49M
Basic Shares Outstanding	56.92K	67.92K	11.28K	157.93K	430.57K	463.74K	2.59M	2.84M	2.94M	4.49M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.1M	4.87M	1.59M	10.92M	18.21M	11.84M	62.69M	41.74M	20.9M	16.04M
Cash & Short-Term Investments	2.36M	4.56M	1.45M	7.52M	17.58M	11.7M	61.16M	39.89M	19.78M	14.27M
Cash Only	2.21M	4.56M	1.45M	7.52M	17.58M	11.67M	14.69M	13.52M	9.29M	6.07M
Short-Term Investments	151.12K	0	0	0	0	24K	45.98M	26.37M	10.49M	8.2M
Accounts Receivable	129.78K	139.01K	88K	3.4M	636K	74K	179K	459K	289K	263K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	-77K	-542	0	-1.35M	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	23K	-26.46K	0	1.35M	77K	76K	76K
Total Non-Current Assets+	418.14K	781.05K	498K	1.84M	1.54M	637K	1.67M	1.33M	1.25M	924K
Property, Plant & Equipment	176.3K	213.32K	219K	385K	1.36M	580K	702K	594K	695K	539K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	14K	0	8.02K	6.62K
Long-Term Investments	0	0	0	120K	130K	4K	55K	0	0	0
Other Non-Current Assets	241.84K	567.73K	279K	1.34M	57K	53K	894K	733K	550.98K	378.38K
Total Assets+	3.52M	5.65M	2.09M	12.76M	19.76M	12.48M	64.35M	43.06M	22.15M	16.96M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	0.61%	-0.63%	5.11%	0.55%	-0.37%	4.16%	-0.33%	-0.49%	-0.23%
Total Current Liabilities+	1.33M	2.36M	2.7M	2.75M	4.12M	1.32M	2.65M	6.75M	4.84M	3.22M
Accounts Payable	589.56K	106.53K	160K	396K	25K	93K	1.34M	1.69M	516K	666K
Days Payables Outstanding	8.2K	956.82	1.15K	2.19K	32.37	424.32	14.33K	10.66K	2.82K	4.56K
Short-Term Debt	0	0	0	0	391K	179K	106K	0	76K	115K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	743.24K	2.25M	2.54M	1.62M	3.05M	-179K	-106K	0	747K	759K
Current Ratio	2.32x	2.07x	0.59x	3.98x	4.42x	9.00x	23.66x	6.18x	4.32x	4.98x
Quick Ratio	2.32x	2.07x	0.59x	4.00x	4.42x	9.00x	24.16x	6.18x	4.32x	4.98x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	37.78K	0	0	210K	725K	358K	237K	91K	316K	209K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	108K	358K	237K	91K	316K	209K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	37.78K	0	0	210K	617K	0	0	0	0	0
Total Liabilities	1.37M	2.36M	2.7M	2.96M	4.85M	1.67M	2.89M	6.84M	5.15M	3.43M
Total Debt+	0	0	0	0	586K	607K	343K	214K	392K	324K
Net Debt	-2.21M	-4.56M	-1.45M	-7.52M	-16.99M	-11.07M	-14.34M	-13.3M	-8.9M	-5.75M
Debt / Equity	-	-	-	-	0.04x	0.06x	0.01x	0.01x	0.02x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-503.81x	-	-1878.40x	-	-2179.00x	-995.50x	-111.34x	-80.83x	-	-
Total Equity+	2.14M	3.29M	-609K	9.8M	14.91M	10.8M	61.47M	36.22M	17M	13.54M
Equity Growth %	-	0.54%	-1.18%	17.1%	0.52%	-0.28%	4.69%	-0.41%	-0.53%	-0.2%
Book Value per Share	37.68	48.48	-53.98	62.09	34.63	23.29	23.70	12.73	5.79	3.02
Total Shareholders' Equity	2.14M	3.29M	-609K	9.8M	12.37M	10.8M	61.47M	36.22M	17M	13.54M
Common Stock	1.26M	1.92M	2.77M	0	0	0	0	0	0	0
Retained Earnings	-47.46M	-52.7M	-62.88M	-78.31M	-17.74M	-23.7M	-36.17M	-63.82M	-88.68M	-102.62M
Treasury Stock	0	0	0	0	0	0	0	-1.22M	0	0
Accumulated OCI	1.07M	1.32M	2.22M	4.44M	872K	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.38M	-3.72M	-8.52M	-14.22M	-16.51M	-5.24M	-12.37M	-20.37M	-23.61M	-15.39M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.5%	-1.29%	-0.67%	-0.16%	0.68%	-1.36%	-0.65%	-0.16%	0.35%
Net Income	-7.5M	-4.73M	-9.81M	-13.8M	-27.21M	-5.95M	-12.48M	-27.65M	-24.22M	-13.95M
Depreciation & Amortization	26.25K	40.64K	51K	66K	281.91K	24K	34K	58K	66.83K	0
Stock-Based Compensation	0	0	0	125K	135K	130K	2.02M	3.21M	1.49M	0
Deferred Taxes	0	0	0	0	2.82M	-579K	-912.63K	-2.96M	0	0
Other Non-Cash Items	574.23K	918.26K	805K	6.27M	2.84M	579K	912.63K	2.96M	-2.27K	670K
Working Capital Changes	-283.12K	506.67K	289K	-3.42M	4.63M	555K	-1.95M	4.01M	-945.56K	-2.11M
Change in Receivables	-568.31K	116.44K	204K	-3.5M	2.31M	-99	-2.06K	-64	903	-487K
Change in Inventory	0	0	0	0	0	99	2.06K	64	0	0
Change in Payables	423.14K	-490.78K	44K	287K	1.08M	68K	1.18M	352K	-1.17M	150K
Cash from Investing+	1.12M	77.63K	-34K	-213K	-95.31K	-62K	-45.19M	19.53M	15.88M	2.3M
Capital Expenditures	-87.25K	-75.81K	-34K	-213K	-95.31K	-38K	-239K	-68K	-3K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	2K	0	-24	1M	0	15.88M	2.3M
Cash from Financing+	4.47M	6.04M	5.24M	20.62M	26.71M	4.75M	61.07M	-808K	3.5M	9.87M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-115.04K	-20.39K	-40.7K	0	26.71M	1.25M	2.44M	143K	9.03K	-46.84K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.47M	-3.8M	-8.55M	-14.44M	-16.61M	-5.28M	-12.61M	-20.44M	-23.61M	-15.39M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	0.49%	-1.25%	-0.69%	-0.15%	0.68%	-1.39%	-0.62%	-0.16%	0.35%
FCF per Share	-131.20	-55.93	-757.82	-91.41	-38.57	-11.39	-4.86	-7.18	-8.04	-3.43
FCF Conversion (FCF/Net Income)	0.98x	0.79x	0.87x	1.03x	0.61x	0.88x	0.99x	0.74x	0.97x	1.10x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	5K	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-349.71%	-174.08%	-730.74%	-300.09%	-220.22%	-46.29%	-34.53%	-56.6%	-91.02%	-91.34%
Return on Invested Capital (ROIC)	-	-	-	-8690%	-14142.89%	-	-39.59%	-61.11%	-123.13%	-139.16%
Debt / Equity	-	-	-	-	0.04x	0.06x	0.01x	0.01x	0.02x	0.02x
Interest Coverage	-503.81x	-	-1878.40x	-	-2179.00x	-995.50x	-111.34x	-80.83x	-	-
FCF Conversion	0.98x	0.79x	0.87x	1.03x	0.61x	0.88x	0.99x	0.74x	0.97x	1.10x

Frequently Asked Questions

Growth & Financials

Chemomab Therapeutics Ltd. (CMMB) grew revenue by 0.0% over the past year. Growth has been modest.

Chemomab Therapeutics Ltd. (CMMB) reported a net loss of $11.8M for fiscal year 2024.

Dividend & Returns

Chemomab Therapeutics Ltd. (CMMB) has a return on equity (ROE) of -91.3%. Negative ROE indicates the company is unprofitable.

Chemomab Therapeutics Ltd. (CMMB) had negative free cash flow of $15.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Chemomab Therapeutics Ltd. (CMMB) 10-Year Financial Performance & Capital Metrics

CMMB • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$15M +42.2%
Net Income -$14M +42.4%
EPS (Diluted) -3.12 +62.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -91.34% -0.4%
ROIC -139.16% -13.0%
Debt/Equity 0.02 +3.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Shares diluted 52.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM21.27%

EPS CAGR

10Y-

5Y-

3Y-

TTM47.91%

ROCE

10Y Avg-195.26%

5Y Avg-65.32%

3Y Avg-82.69%

Latest-94.91%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	26.25K	40.64K	51K	66K	281.91K	80K	34.02K	57.77K	66.83K	53.25K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-26.25K	-40.64K	-51K	-65.78K	-282K	-80K	-34.02K	-57.77K	-66.83K	-53.25K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.55%	-0.25%	-0.29%	-3.29%	0.72%	0.57%	-0.7%	-0.16%	0.2%
Operating Expenses+	7.11M	4.59M	9.34M	12.97M	19.33M	5.97M	12.37M	28.53M	25.46M	14.74M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	1.14M	2.25M	3.11M	5.46M	5.98M	1.29M	6.03M	11.56M	7.08M	3.41K
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	5.96M	2.34M	6.23M	7.51M	13.35M	4.68M	6.33M	16.98M	18.38M	11.33K
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	14.72M
Operating Income+	-7.13M	-4.63M	-9.39M	-13.04M	-19.61M	-5.97M	-12.37M	-28.53M	-25.46M	-14.74M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	0.35%	-1.03%	-0.39%	-0.5%	0.7%	-1.07%	-1.31%	0.11%	0.42%
EBITDA+	-7.11M	-4.59M	-9.34M	-12.97M	-19.33M	-5.95M	-12.33M	-28.48M	-25.39M	-14.69M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	0.35%	-1.03%	-0.39%	-0.49%	0.69%	-1.07%	-1.31%	0.11%	0.42%
D&A (Non-Cash Add-back)	26.25K	40.64K	51K	66K	281.91K	24K	34.02K	57.77K	67K	53.25K
EBIT	-7.49M	-4.61M	-9.55M	-13.42M	-27.2M	-5.97M	-12.37M	-28.53M	-25.46M	-14.01M
Net Interest Income+	-13.13K	0	-4K	0	384K	14K	-111K	-1.38K	1.23M	797.77K
Interest Income	1.03K	521	1K	0	393K	20K	65	351.62K	1.24M	797.77K
Interest Expense	14.16K	0	5K	0	9K	6K	111.08K	353K	0	0
Other Income/Expense	-369K	36.33K	-91.71K	-456K	-7.6M	21K	-111K	353K	1.24M	794K
Pretax Income+	-7.5M	-4.61M	-9.56M	-5.87M	-27.21M	-5.95M	-12.48M	-28.18M	-24.22M	-13.95M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-3	136.24K	323K	306K	0	0	0	-534K	0	0
Effective Tax Rate %	1%	1.03%	1.03%	2.35%	1%	1%	1%	0.98%	1%	1%
Net Income+	-7.5M	-4.73M	-9.81M	-13.8M	-27.21M	-5.95M	-12.48M	-27.65M	-24.22M	-13.95M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	0.37%	-1.07%	-0.41%	-0.97%	0.78%	-1.1%	-1.22%	0.12%	0.42%
Net Income (Continuing)	-7.5M	-4.75M	-9.88M	-5.87M	-27.21M	-5.95M	-12.49M	-27.65M	-24.22M	-13.95M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-131.76	-69.00	-875.98	-87.09	-63.20	-25.21	-4.80	-9.68	-8.22	-3.12
EPS Growth %	-	0.48%	-11.7%	0.9%	0.27%	0.6%	0.81%	-1.02%	0.15%	0.62%
EPS (Basic)	-131.76	-69.00	-875.98	-87.09	-63.20	-25.21	-4.80	-9.68	-8.22	-3.12
Diluted Shares Outstanding	56.92K	67.92K	11.28K	157.93K	430.57K	463.74K	2.59M	2.84M	2.94M	4.49M
Basic Shares Outstanding	56.92K	67.92K	11.28K	157.93K	430.57K	463.74K	2.59M	2.84M	2.94M	4.49M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.1M	4.87M	1.59M	10.92M	18.21M	11.84M	62.69M	41.74M	20.9M	16.04M
Cash & Short-Term Investments	2.36M	4.56M	1.45M	7.52M	17.58M	11.7M	61.16M	39.89M	19.78M	14.27M
Cash Only	2.21M	4.56M	1.45M	7.52M	17.58M	11.67M	14.69M	13.52M	9.29M	6.07M
Short-Term Investments	151.12K	0	0	0	0	24K	45.98M	26.37M	10.49M	8.2M
Accounts Receivable	129.78K	139.01K	88K	3.4M	636K	74K	179K	459K	289K	263K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	-77K	-542	0	-1.35M	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	23K	-26.46K	0	1.35M	77K	76K	76K
Total Non-Current Assets+	418.14K	781.05K	498K	1.84M	1.54M	637K	1.67M	1.33M	1.25M	924K
Property, Plant & Equipment	176.3K	213.32K	219K	385K	1.36M	580K	702K	594K	695K	539K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	14K	0	8.02K	6.62K
Long-Term Investments	0	0	0	120K	130K	4K	55K	0	0	0
Other Non-Current Assets	241.84K	567.73K	279K	1.34M	57K	53K	894K	733K	550.98K	378.38K
Total Assets+	3.52M	5.65M	2.09M	12.76M	19.76M	12.48M	64.35M	43.06M	22.15M	16.96M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	0.61%	-0.63%	5.11%	0.55%	-0.37%	4.16%	-0.33%	-0.49%	-0.23%
Total Current Liabilities+	1.33M	2.36M	2.7M	2.75M	4.12M	1.32M	2.65M	6.75M	4.84M	3.22M
Accounts Payable	589.56K	106.53K	160K	396K	25K	93K	1.34M	1.69M	516K	666K
Days Payables Outstanding	8.2K	956.82	1.15K	2.19K	32.37	424.32	14.33K	10.66K	2.82K	4.56K
Short-Term Debt	0	0	0	0	391K	179K	106K	0	76K	115K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	743.24K	2.25M	2.54M	1.62M	3.05M	-179K	-106K	0	747K	759K
Current Ratio	2.32x	2.07x	0.59x	3.98x	4.42x	9.00x	23.66x	6.18x	4.32x	4.98x
Quick Ratio	2.32x	2.07x	0.59x	4.00x	4.42x	9.00x	24.16x	6.18x	4.32x	4.98x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	37.78K	0	0	210K	725K	358K	237K	91K	316K	209K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	108K	358K	237K	91K	316K	209K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	37.78K	0	0	210K	617K	0	0	0	0	0
Total Liabilities	1.37M	2.36M	2.7M	2.96M	4.85M	1.67M	2.89M	6.84M	5.15M	3.43M
Total Debt+	0	0	0	0	586K	607K	343K	214K	392K	324K
Net Debt	-2.21M	-4.56M	-1.45M	-7.52M	-16.99M	-11.07M	-14.34M	-13.3M	-8.9M	-5.75M
Debt / Equity	-	-	-	-	0.04x	0.06x	0.01x	0.01x	0.02x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-503.81x	-	-1878.40x	-	-2179.00x	-995.50x	-111.34x	-80.83x	-	-
Total Equity+	2.14M	3.29M	-609K	9.8M	14.91M	10.8M	61.47M	36.22M	17M	13.54M
Equity Growth %	-	0.54%	-1.18%	17.1%	0.52%	-0.28%	4.69%	-0.41%	-0.53%	-0.2%
Book Value per Share	37.68	48.48	-53.98	62.09	34.63	23.29	23.70	12.73	5.79	3.02
Total Shareholders' Equity	2.14M	3.29M	-609K	9.8M	12.37M	10.8M	61.47M	36.22M	17M	13.54M
Common Stock	1.26M	1.92M	2.77M	0	0	0	0	0	0	0
Retained Earnings	-47.46M	-52.7M	-62.88M	-78.31M	-17.74M	-23.7M	-36.17M	-63.82M	-88.68M	-102.62M
Treasury Stock	0	0	0	0	0	0	0	-1.22M	0	0
Accumulated OCI	1.07M	1.32M	2.22M	4.44M	872K	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.38M	-3.72M	-8.52M	-14.22M	-16.51M	-5.24M	-12.37M	-20.37M	-23.61M	-15.39M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.5%	-1.29%	-0.67%	-0.16%	0.68%	-1.36%	-0.65%	-0.16%	0.35%
Net Income	-7.5M	-4.73M	-9.81M	-13.8M	-27.21M	-5.95M	-12.48M	-27.65M	-24.22M	-13.95M
Depreciation & Amortization	26.25K	40.64K	51K	66K	281.91K	24K	34K	58K	66.83K	0
Stock-Based Compensation	0	0	0	125K	135K	130K	2.02M	3.21M	1.49M	0
Deferred Taxes	0	0	0	0	2.82M	-579K	-912.63K	-2.96M	0	0
Other Non-Cash Items	574.23K	918.26K	805K	6.27M	2.84M	579K	912.63K	2.96M	-2.27K	670K
Working Capital Changes	-283.12K	506.67K	289K	-3.42M	4.63M	555K	-1.95M	4.01M	-945.56K	-2.11M
Change in Receivables	-568.31K	116.44K	204K	-3.5M	2.31M	-99	-2.06K	-64	903	-487K
Change in Inventory	0	0	0	0	0	99	2.06K	64	0	0
Change in Payables	423.14K	-490.78K	44K	287K	1.08M	68K	1.18M	352K	-1.17M	150K
Cash from Investing+	1.12M	77.63K	-34K	-213K	-95.31K	-62K	-45.19M	19.53M	15.88M	2.3M
Capital Expenditures	-87.25K	-75.81K	-34K	-213K	-95.31K	-38K	-239K	-68K	-3K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	2K	0	-24	1M	0	15.88M	2.3M
Cash from Financing+	4.47M	6.04M	5.24M	20.62M	26.71M	4.75M	61.07M	-808K	3.5M	9.87M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-115.04K	-20.39K	-40.7K	0	26.71M	1.25M	2.44M	143K	9.03K	-46.84K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.47M	-3.8M	-8.55M	-14.44M	-16.61M	-5.28M	-12.61M	-20.44M	-23.61M	-15.39M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	0.49%	-1.25%	-0.69%	-0.15%	0.68%	-1.39%	-0.62%	-0.16%	0.35%
FCF per Share	-131.20	-55.93	-757.82	-91.41	-38.57	-11.39	-4.86	-7.18	-8.04	-3.43
FCF Conversion (FCF/Net Income)	0.98x	0.79x	0.87x	1.03x	0.61x	0.88x	0.99x	0.74x	0.97x	1.10x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	5K	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-349.71%	-174.08%	-730.74%	-300.09%	-220.22%	-46.29%	-34.53%	-56.6%	-91.02%	-91.34%
Return on Invested Capital (ROIC)	-	-	-	-8690%	-14142.89%	-	-39.59%	-61.11%	-123.13%	-139.16%
Debt / Equity	-	-	-	-	0.04x	0.06x	0.01x	0.01x	0.02x	0.02x
Interest Coverage	-503.81x	-	-1878.40x	-	-2179.00x	-995.50x	-111.34x	-80.83x	-	-
FCF Conversion	0.98x	0.79x	0.87x	1.03x	0.61x	0.88x	0.99x	0.74x	0.97x	1.10x

Frequently Asked Questions

Growth & Financials

Chemomab Therapeutics Ltd. (CMMB) grew revenue by 0.0% over the past year. Growth has been modest.

Chemomab Therapeutics Ltd. (CMMB) reported a net loss of $11.8M for fiscal year 2024.

Dividend & Returns

Chemomab Therapeutics Ltd. (CMMB) has a return on equity (ROE) of -91.3%. Negative ROE indicates the company is unprofitable.

Chemomab Therapeutics Ltd. (CMMB) had negative free cash flow of $15.4M in fiscal year 2024, likely due to heavy capital investments.